Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

  • Adam-Artigues, Anna
  • Garrido-Cano, Iris
  • Carbonell-Asins, Juan Antonio
  • Lameirinhas, Ana
  • Simón, Soraya
  • Ortega-Morillo, Belén
  • Martínez, María Teresa
  • Hernando, Cristina
  • Constâncio, Vera
  • Burgues, Octavio
  • Bermejo, Begoña
  • Henrique, Rui
  • Lluch, Ana
  • Jerónimo, Carmen
  • Eroles, Pilar
  • Cejalvo, Juan Miguel
[EN] The early diagnosis of breast cancer is essential to improve patients' survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs., This study was financed by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds (PI18/01219 to P.E. and CB16/12/00481 to A.Ll.) and from the Research Centre of the Portuguese Oncology Institute of Porto (PI 74-CBEG-CI-IPOP-19-2015 to C.J.). A.A.-A. and A.L. were funded by Asociación Española Contra el Cáncer (PRDVA18013LLUC and PRDVA19016LAME). V.C. was funded by Liga Portuguesa Contra o Cancro/Fundação PT. J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). The authors are grateful to INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and Valencian Biobanking Network integrated into the Spanish National Biobanks Network and nursing staff from all institutions for collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

  • Lameirinhas, Ana
  • Torres-Ruiz, Sandra
  • Garrido-Cano, Iris
  • Hernando, Cristina
  • Martínez, Maria Teresa
  • Rovira, Ana
  • Albanell, Joan
  • Zazo, Sandra
  • Rojo, Federico
  • Bermejo, Begoña
  • Lluch, Ana
  • Cejalvo, Juan Miguel
  • Tormo, Eduardo
  • Eroles, Pilar
[EN] The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients' worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/FASN axis as a potential therapeutic target in combination with anti-HER2 agents to overcome trastuzumab resistance and to improve treatment response in HER2-positive breast cancer patients., This work was supported by the Spanish Government and cofinanced by FEDER Funds (AES Program, grants PI21/01351, PI21/00002, PI21/00142; CIBERONC, Biomedical Research Networking Centre for Cancer CB16/12/00241 and CB16/12/00481). AL was founded by Asociacion Espanola Contra el Cancer (PRDVA19016LAME). STR was founded by Conselleria d'Educacio, Investigacio, Cultura iEsport, Generalitat Valenciana (ACIF/2019/119). IGC was founded by Margarita Salas postdoctoral grant (European Union-Next generation EU). JMC was founded by Sociedad Espanola de Oncologia Medica (Rio Hortega-SEOM).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer

  • Torres-Ruiz, Sandra
  • Garrido-Cano, Iris
  • Lameirinhas, Ana
  • Burgués, Octavio
  • Hernando, Cristina
  • Martínez, Maria Teresa
  • Rojo, Federico
  • Bermejo, Begoña
  • Tapia, Marta
  • Carbonell-Asins, Juan Antonio
  • Peña, Carlos Javier
  • Lluch, Ana
  • Cejalvo, Juan Miguel
  • Tormo, Eduardo
  • Eroles, Pilar
[EN] Despite progress in breast cancer treatment, a significant portion of patients still relapse because of drug resistance. The involvement of microRNAs in cancer progression and chemotherapy response is well established. Therefore, this study aimed to elucidate the dysregulation of the microRNA-449 family (specifically, microRNA-449a, microRNA-449b-5p, and microRNA-449c-5p) and its impact on resistance to doxorubicin, a commonly used chemotherapeutic drug for the treatment of triple-negative breast cancer. We found that the microRNA-449 family is downregulated in triple-negative breast cancer and demonstrated its potential as a diagnostic biomarker. Besides, our findings indicate that the downregulation of the microRNA-449 family is mediated by the microRNAs-449/SIRT1-HDAC1 negative feedback loop. Moreover, it was found that the microRNA-449 family dysregulates the fatty acid metabolism by targeting ACSL4, which is a potential prognostic biomarker that mediates doxorubicin response through regulation of the drug extrusion pump ABCG2. Altogether, our results suggest that the microRNA-449 family might be a potential therapeutic target for the treatment of triple-negative breast cancer since it is implicated in doxorubicin response through ACSL4/ABCG2 axis regulation. Ultimately, our results also highlight the value of microRNAs-449 and ACSL4 as diagnostic and prognostic biomarkers in triple-negative breast cancer., This work was supported by the Spanish Government and cofinanced by FEDER Funds (AES Program, grants PI21/01351, PI21/00142, CIBERONC, Biomedical Research Networking Centre for Cancer CB16/12/00241, and CB16/12/00481). STR was founded by Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (ACIF/2019/119). IGC was founded by Margarita Salas's postdoctoral grant (European Union-Next generation EU). AL was founded by Asociacion Espanola Contra el Cancer(PRDVA19016LAME). JMC was founded by Sociedad Espanola de Oncologia Medica(Rio Hortega-SEOM)